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Dental opioid prescribing rates 
after the up-scheduling of codeine 
in Australia
L. teoh1 ✉, S. Hollingworth2, R. Marino1 & M. J. Mccullough1
the misuse of pharmaceutical opioids is a major public health issue. in Australia, codeine was re-
scheduled on 1 February 2018 to restrict access; it is now only available on prescription. The aim of this 
study was to measure the change in dental opioid prescriptions, one year before and after the codeine 
re-scheduling in Australia and to assess dental prescribing rates of opioids for 2018 by population and 
by clinician. Data was extracted for dental opioids for the year immediately prior and after the codeine 
up-schedule (1 February 2017-31 January 2019) from the publicly-available national prescription 
database (Pharmaceutical Benefits Scheme). Descriptive statistics, T-tests and odds ratios were used 
to identify significant prescribing differences. Codeine, codeine/paracetamol, oxycodone and tramadol 
use increased significantly the year after the codeine restriction than the previous year (13.8–101.1%). 
Australian dentists prescribed 8.6 prescriptions/1,000 population in 2018, with codeine/paracetamol 
accounting for most prescriptions (96%). The significant increase in opioid prescribing highlights that 
Australian dentists may be contributing to the misuse of pharmaceutical opioids. Educational efforts 
should be targeted at the appropriate use of opioids and patient selection. Dentists should be added to 
the prescription monitoring system SafeScript so they can make informed decisions for patients who 
are potentially misusing opioids.
Australia’s opioid crisis has been well documented; hospitalisations for pharmaceutical opioid poisoning sur-
passed those of heroin use and the misuse of pharmaceutical drugs as the most common reason for people to 
enter drug and alcohol treatment programs in Australia1. Pharmaceutical opioid deaths are now increasing 
at a greater rate than that due to heroin use as shown in a retrospective analysis from the National Coronial 
Information Systems between 2001 to 20122, and three people die every day from drug-related events involving 
pharmaceutical opioids3. Forty percent of deaths due to prescription opioid use were associated with a valid pre-
scription of oxycodone for non-cancer pain (2001 to 2011)1.
The main source of opioids for non-medical use is leftover tablets of legitimate prescriptions sourced through 
social networks such as family and friends4. In Australia, codeine products, both over the counter (OTC) and 
prescription, comprised the most commonly misused pharmaceutical products, followed by oxycodone and 
tramadol5. Codeine is the most frequently used opioid analgesic in Australia6, and ranks fourth behind meth-
adone, oxycodone, and morphine in being implicated in pharmaceutical opioid overdose deaths2. Nearly three 
in five (56%) codeine-containing analgesic products were purchased OTC in 20137. Prescription-only codeine 
utilisation was not accounted for in 21% of claims on Australia’s national medicines subsidy, the Pharmaceutical 
Benefits Scheme (PBS)7. A case series study reported that two in five (39%) patients with an opioid addiction were 
dependent on codeine alone8. The rate of codeine-related deaths increased several fold over ten years (3.5/million 
in 2000; 8.7/million in 2009)9. In response to the misuse, risks and toxicity, the Therapeutic Goods Administration 
(TGA) up-scheduled codeine from OTC and prescription to prescription only on 1 February 201810.
Dentists in Australia have increasingly been prescribing opioids; the most common product is codeine with 
paracetamol (Panadeine Forte)11. This pattern continues despite non-steroidal anti-inflammatory drugs (NSAID) 
being more appropriate for dental pain12,13. NSAIDs, alone or in combination with paracetamol, were found to 
be the most effective for dental pain while minimising adverse effects in an overview of systematic reviews14. 
Irrespective, dental opioid prescribing increased 30% between 2013 and 201611.
The legislative change to codeine scheduling appears to have reduced codeine misuse as highlighted in a recent 
analysis of monthly opioid exposure calls to the New South Wales Poisons Information Centre15. Additionally, 
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studies of medical opioid prescribing indicate that there is no change in rates of dispensed opioid prescrip-
tions after the legislative change compared to before (from January 2016 to December 2018)16. However, dental 
prescribing of opioids is increasing and some dentists are inappropriately preferencing the use of opioids over 
NSAIDs as recommended in the current Australian therapeutic guidelines17. The effect of the codeine resched-
uling change on dental opioid prescribing is unknown. Thus, there were two aims of this study: 1) to assess pre-
scribing rates of dental opioids in 2018 and 2) to analyse the dispensed use of dental opioids, one year before and 
one year after the up-scheduling of codeine.
Method
This study involved an analysis of dispensed prescriptions to the Australian population from outpatient phar-
macies from a nationally-representative database. The data used in this study was obtained from Medicare 
Australia administered by the Australian Government Department of Health. As the data was publicly available 
and aggregated, no ethical approval was required. The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) reporting guideline was followed.
Data sources. The Department of Health provides a national database on prescribed medicines in Australia 
that are recorded under the Pharmaceutical Benefits Scheme (PBS)18. We analysed opioids subsidised by the 
Australian Government for dental prescribers listed on the PBS including codeine, codeine 30 mg/paracetamol 
500 mg, hydrocodone, morphine, oxycodone, and tramadol. For the first part of the study, we assessed opioid use 
one year prior immediately prior to and one year after the change in codeine re-scheduling to prescription only 
(1 February 2018) by extracting monthly data of PBS dispensed use of dental opioids from 1 February 2017 to 31 
January 2019. In Australia, the government subsidises the cost of medicines listed on the PBS. Some medicines 
(and for specific indications) are not subsidised and so the prescriber will issue a ‘private’ prescription where 
the consumer funds the full cost of the medicine. These are not recorded under PBS data and therefore are not 
accounted for in the analysis. PBS prescriptions account for approximately 75% of dispensed medicine use in 
Australia, where prescriptions are dispensed in hospital settings and outpatient pharmacies19. However, most 
dental prescriptions would be from community pharmacies, of which PBS subsidised prescriptions represent 
around 93% of community prescriptions20. Therefore, the majority of dental prescriptions (closer to 93%) would 
be accounted for in this analysis. The ‘date of supply’ dataset was accessed as this is recommended when analysing 
medicine use19. Given the variations in processing, the dataset was accessed six months after the end study date 
(i.e. 1 August 2019)19. Dentists are urged to follow the Australian therapeutic guidelines17 but they are free to 
prescribe whatever medicines they choose. Despite the PBS being a national formulary, the laws governing the 
supply and prescribing of medicines varies among the states of Australia. The relevant difference is that dentists 
in Queensland are prohibited from prescribing oxycodone21.
For the second part of the study, we assessed the dental prescribing rates by population and clinician from 1 
January to 31 December 2018. The number of registered dental practitioners were obtained from the Australian 
Health Practitioner Regulation Agency22 and the population value from the Australian Bureau of Statistics23.
outcome measures. Three outcomes were measured: 1) dental opioid use for 2018 using the standardised 
defined daily dose (DDD)/1,000 inhabitants/day metric (see below); 2) prescribing rates for 2018 by population 
and by dentist; 3) the mean percentage difference for each individual opioid for the year before and after the 
rescheduling change.
Statistical analysis. We extracted and analysed data using Microsoft Excel. Descriptive statistics were used 
to determine dental opioid use for 2018 by population and by clinician. Medicine use was calculated using the 
accepted and standardised metric of the DDD per 1,000 populations per day18,24. The DDD value for each med-
icine was obtained from the World Health Organization Collaborating Centre for Drug Statistics Methodology; 
it is the average maintenance dose per day for the main indication in adults24. The DDD metric is acceptable to 
reflect utilisation for the opioids listed except oxycodone, as the WHO DDD has been found to be two to seven 
times higher than actual doses used for oxycodone25. Therefore, for oxycodone only, doses were converted to oral 
morphine equivalents and the morphine DDD used to calculate the DDD/1000 population/day metric to indicate 
utilisation26. In Australia, the number of tablets per pack is standardised and most products are prescribed in 
PBS-specified packs.
T-tests (two-tailed) were used to identify significant differences between the number of opioid prescriptions 
one year before and after the re-scheduling change; p < 0.05 was considered significant. Odds ratios were also 
used to quantify the proportionate change for each opioid for the year after the codeine restriction compared 
to the previous year, relative to the increase the population. The mid-year population was used, with the data 
obtained from the ABS.
Results
Dental opioid dispensed use in Australia. There were 213,933 dispensed dental opioid prescriptions in 
2018 in Australia. Australian dentists prescribed 8.6 opioid prescriptions/1,000 population, 12.1 prescriptions/
dentist and 0.1 total DDD/1000 inhabitants/day. Australian dentists preferentially prescribed the codeine 30 mg/
paracetamol 500 mg product (accounted for 205,189 prescriptions, 96% of opioid prescriptions), followed by 
oxycodone (6,050 prescriptions, 2.8% of opioid prescriptions) and tramadol (2,490 prescriptions, 1.2% of opioid 
prescriptions) (Table 1).
trends in dispensed use of dental opioids. When comparing the year after the up-scheduling of codeine 
to the previous year, there was a significant increase in the mean difference for the most commonly dispensed 
four opioids. The use of codeine, codeine/paracetamol, oxycodone and tramadol increased significantly over the 
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two-year period (codeine: 101.1% mean increase from 8.7 to 17.5 prescriptions, p = 0.002; codeine 30 mg/par-
acetamol 500 mg: 20.6% mean increase from 14,337.0 to 17,284.5 prescriptions., p < 0.0001; oxycodone: 23.5% 
mean increase from 416.1 to 514.0 prescriptions, p < 0.001; tramadol: 13.8% mean increase from 183.1 to 208.3 
prescriptions, p = 0.03). This occurred despite the increase in the population and number of clinicians over the 
same period being much lower (1.6% and 3.1% respectively). (Table 2, Figs. 1 and 2). The use of hydromorphone 
and morphine had low use. When comparing the year before and after the re-scheduling change, hydromorphone 
use stayed the same with one prescription dispensed both the year before and after the change; morphine use 
decreased from 15 prescriptions to 3 prescriptions respectively.
When assessing the relative proportions of dispensed opioids, there was an increase in the relative proportions 
of opioids prescribed the year after the codeine restriction compared to the previous year, adjusted for the popula-
tion increase. (codeine: OR: 2.0; codeine/paracetamol: OR: 1.2; oxycodone OR: 1.2; tramadol OR: 1.1).
Discussion
This is the first study to assess the effect of the codeine up-schedule on dental opioid prescribing in Australia. 
There was a substantial increase in dispensed dental opioid use after the up-scheduling of codeine with rela-
tively smaller increases in the population and clinician numbers. As expected, this was significant for codeine 
and codeine with paracetamol, but also evident for oxycodone and tramadol. This increase occurred despite the 
Australian therapeutic guidelines indicating that opioids are not to be used first line to treat dental pain17, and 
tramadol is also not recommended17.
Opioid
Number of 
prescriptions
Percentage of 
prescriptions
Number of 
prescriptions/1000 
population
Number of 
prescriptions/
dentist
Total 
DDD/1000/
DAY
Codeine 199 0.1 0.0 0.0 0.0
Codeine/Paracetamol 205,189 95.9 8.2 11.6 0.1
Hydromorphone 1 0.0 0.0 0.0 0.0
Morphine 4 0.0 0.0 0.0 0.0
Oxycodone 6,050 2.8 0.2 0.3 0.0
Tramadol 2,490 1.2 0.1 0.1 0.0
Total 213,933 100.0 8.6 12.1 0.1
Table 1. Dispensed prescriptions for opioids in Australian in 2018 by population, number of dentists and 
defined daily dose per 1,000 population per day. Mid-year population for Australia 2018: 24,992,400.
Opioid
Mean No. prescriptions 1 Feb 
2017-1 Jan 2019 (95% CI)
Mean No. prescriptions 1 Feb 
2017-31 Jan 2019 (95% CI)
Annual % 
increase in 
mean p-value Odds ratio*
Codeine 30 mg 8.7 (6.7-10.6) 17.5 (12.5-22.5) 101.1 0.002 2.0
Codeine 30 mg with 
paracetamol 500 mg 14,337.0 (13,798.5-14,875.5) 17284.5 (16,639.6-17,929.4) 20.6 <0.0001 1.2
Oxycodone 416.1 (381.8-450.4) 514.0 (477.9-550.1) 23.5 <0.001 1.2
Tramadol 183.1 (170.4-195.8) 208.3 (188.5-228.2) 13.8 0.03 1.1
Table 2. Annual increase in dispensed opioids in Australia from 1 February 2017 to 31 January 2019. *The 
proportionate change of each opioid compared the total year after the re-scheduling change to the previous year.
Figure 1. Dispensed dental prescriptions of codeine 30 mg/paracetamol 500 mg between 1 February 2017 and 
31 January 2019. *Codeine was up-scheduled on 1 February 2018.
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Multiple studies have confirmed that NSAIDs alone or in combination with paracetamol are more effec-
tive than opioid combinations for dental pain27 and as such opioids are not first line treatment in the current 
Australian guidelines17. Moreover, analgesic doses of codeine provide no extra pain relief in the surgical extrac-
tion of third molars compared to paracetamol and ibuprofen alone28. Furthermore, patients undergoing third 
molar extractions who received the opioid combination products had significantly more adverse effects compared 
to the patients who received the NSAID combination products27. Given the limited role of opioids in dental pain 
and that the vast majority of dental conditions require active treatment alone where medicines would only be 
adjunctive17, theoretically, the dental prescribing of opioids should not be increasing at a rate greater than the 
population change. Previous longitudinal studies of dental opioid prescribing in Australia showed increases in 
the use of opioids11 but this does not explain the significant increase after the codeine up-schedule. About one 
in four dentists in Australia (16-27%) would preference the use of analgesics only (paracetamol, paracetamol/
codeine, tramadol or oxycodone) for dental pain, instead of NSAIDs29. Australian dentists tend to recommend 
tramadol if their patient is allergic or finds codeine ineffective30, despite both medicines requiring transformation 
by cytochrome P450 2D6 to the active metabolites. The pharmacogenomic variability of cytochrome P450 2D6 
is well established and therefore patients who have inherited two non-functional alleles of this enzyme will likely 
find both medicines ineffective. In addition, other non-clinical factors have been identified for prescribing by 
Australian dentists, such as patient pressure, fear of litigation, and the desire by dentists to make patients feel well 
managed30.
While the increase in the use of paracetamol/codeine may be partly accounted for by the up-scheduling of 
codeine, the large increase suggests that dentists may also be inappropriately prescribing opioids, or some people 
may be acquiring opioids from dentists for misuse31. A case series analysis of people who sought help for opioid 
dependence showed that many initiated codeine for the treatment of headaches and dental pain8. A previous 
study in Boston, USA showed that one in eight (12%) people who presented to the emergency department with 
backache, dental pain or headache were seeking to acquire an opioid drug31. A pre-filled opioid prescription, 
given prior to the extraction of wisdom teeth, is an independent risk factor for persistent opioid use32. Dental 
opioid prescriptions may be associated with subsequent opioid abuse in adolescents and young adults33.
Dental prescribing of opioids varies substantially across countries. Underscoring the findings from this anal-
ysis of dental opioid prescribing rates, a recent study by Suda et al. compared opioid prescribing between US and 
English dentists in 201634. Australian dentists prescribe around four times less than those in the US (35.4 opioid 
prescriptions/1,000 US population versus 8.6 opioid prescriptions/1,000 Australian population) and almost five 
times less than those in the US when adjusting by clinician (58.2 opioid prescriptions/US dentist versus 12.1 opi-
oid prescriptions/Australian dentist)34. In addition, US dentists prescribe a larger range of opioids and long-acting 
opioids than Australian dentists34. Notwithstanding this substantial difference to US dentists, Australian dentists 
prescribe 21 times more opioids than English dentists when adjusted for population (0.5 prescriptions/1,000 
English population), and about ten times the rate when adjusting by clinician34. This vast difference in prescribing 
rates occurs despite all three countries displaying similar levels of oral health as measured by such as decayed, 
missing and filled teeth indexes, and levels of edentulousness35. Suda et al. noted that one major difference among 
prescribing practises is that English dentists are restricted to prescribe from a medicine formulary; they can only 
prescribe dihydrocodeine on the NHS34. Nevertheless, such a striking contrast must be questioned whether this 
is due to prescribing practices alone, or potentially opioid seeking behaviour across these different countries. 
Further, it may well be that there are much higher levels of opioid use in England as these medications are readily 
available over the counter and thus their use merely not measurable.
The limitations of this study are that the Australian PBS data only captures prescribing on the PBS and does 
not include prescriptions that are privately funded. Furthermore, no prescription would be generated where the 
dentist both prescribed and supplied the medicine directly to patients. It is expected that these sources of pre-
scriptions will be relatively low; dental dispensing is rare in Australia. Prescription details such as dose, frequency 
and duration of treatment were not available therefore it was not possible to assess the appropriateness of the 
prescriptions. These data are not linked to morbidity or mortality data so it is not possible to ascertain any link 
Figure 2. Dispensed dental prescriptions of codeine, oxycodone and tramadol between 1 February 2017 and 31 
January 2019. *Codeine was up-scheduled on 1 February 2018.
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between dental opioid prescribing and opioid misuse. Nevertheless, these data allowed for international compar-
isons and demonstrated prescribing trends in most of the population.
This study has substantial public health implications. It should initiate a call to action for dentists regarding 
their role in responsible opioid prescribing, as well as to re-evaluate the recommendations of opioids in dental 
practice. Given the established misuse of pharmaceutical opioids in Australia5 and other countries, and the asso-
ciated public health burden, dentists should only prescribe opioids if NSAIDs and paracetamol have not been 
effective or cannot be tolerated; they should ensure a true therapeutic need exists. Continuing education efforts 
could be directed towards the appropriate use and limitations of opioids in general dental practice, with future 
research aimed at developing strategies to improve opioid prescribing among dentists at an individual level.
Strategies could be implemented for the early identification of people who are at higher risk of developing 
opioid dependence. Opioid-dependent individuals tend to also have co-morbidities of pre-existing chronic pain 
and psychiatric conditions8. High rates of concomitant prior mental health, substance use and chronic pain 
issues were recorded for these deaths due to codeine toxicity in a prospective study from the National Coronial 
Information System9. Given that the predominant source of drugs for misuse is mostly through leftover pills from 
legitimate prescriptions sourced through social networks4, manufacturers could consider the formulation of opi-
oids in smaller pack sizes to reduce the number of leftover pills from a prescription.
One other measure to assist with the prescribing of medicines prone to misuse is the Safe Script program36, 
which is  obligatory in the Australian states of Victoria and Tasmania from April 2020. This initiative allows pre-
scribers to access real-time prescription monitoring for all patients who acquire medicines prone to misuse from 
each prescriber and pharmacist to assist with ‘doctor shopping’ and to prevent the increased acquisition of these 
drugs from multiple clinicians. The initiative is only implemented in two Australian states and includes medical 
doctors, nurses, and pharmacists only. Given the significant increase in the use of codeine since the scheduling 
change, including dentists in the program will assist them to make more informed decisions when prescribing 
drugs of dependence to people who are seeking opioids for non-medical use.
conclusion
Underscoring the opioid crisis in Australia, this study illustrates how the increased prescribing of opioids by den-
tists, especially since the codeine restriction, may be contributing to the epidemic and how dental prescriptions 
can be a source of misuse. While guidelines are in place, further restrictions from the PBS such as prescribing 
authority prescriptions for selected indications and restricted quantities are some ways to curtail prescribing 
and limit the number of tablets prescribed. The prescription monitoring system - Safescript - should include 
dentists to allow them to be aware when prescribing opioids for people who acquire them for non-medical use. 
Consideration should be given when prescribing opioids for patients who have chronic pain, and procedures 
established for the early identification of people who may be prone to opioid dependence. Further research is 
needed to investigate the appropriateness of prescribing practices, and both undergraduate and continuing edu-
cation of dentists should be targeted about the role of opioids in dental pain management.
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